BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1808 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials. Participants will receive infusions of with BI-1808 as a single agent, BI-1808 in combination with pembrolizumab and BI-1808 in combination with pembrolizumab and paclitaxel every 3 we

Trial Details

NCT ID
NCT04752826
Phase
PHASE1 / PHASE2
Sponsor
BioInvent International AB
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • BI-1808
  • Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • New York, New York, United States|40.71427,-74.00597
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Copenhagen, Denmark|55.67594,12.56553
  • Herlev, Denmark|55.72366,12.43998

Key Eligibility Criteria

  • Able and willing to provide written informed consent.
  • Aged 18 years or older.
  • Histologically confirmed advanced or metastatic malignancy eligible for an enrolling study cohort.
  • Disease progression following, intolerance of, ineligibility for, or refusal of applicable standard therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →